Chen L, Li H, Zhang H, Yang H, Qiun J, Li Z et al.
JAMA 2025; 333: 673-681.
The addition of camrelizumab to the present neoadjuvant regimen increased the rate of pathologically complete response: 56.8 versus 44.7 per cent, P=0.004 in this study that included 441 women.
Comment: Higher complete response rate may improve survival.
.png)
.jpg){kind=logo}
